| Jun 14 |
Actinium Highlights Oral Presentation at EHA 2024 Annual Congress Featuring Improved Outcomes in TP53 Positive Patients Receiving Iomab-B in the Phase 3 SIERRA Trial
|
| Jun 11 |
Actinium Announces Results of Actimab-A + CLAG-M Combination Trial Highlighted in Oral Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting
|
| Jun 10 |
Under-$10 Picks: 3 Biotech Stocks That Can Double Before the End of 2024
|
| Jun 10 |
Actinium Highlights Mutation Data from the Phase 3 SIERRA Trial of Iomab-B and Novel Linker Technology to Support Solid Tumor Antibody Radiation Conjugate Development at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting
|
| Jun 7 |
Meme Mania Meets Medicine: 3 Biotech Stocks Primed to Soar
|
| Jun 4 |
Is Affimed (AFMD) Outperforming Other Medical Stocks This Year?
|
